Bluejay Diagnostics (BJDX) Share-based Compensation Growth (3y) (2023 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.10% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 5.54% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 5.09% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 14.70% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 5.29% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 7.15% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 13.40% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 12.36% |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -90.55% |
| Sep 30, 2025 | -88.26% |
| Jun 30, 2025 | -26.30% |
| Mar 31, 2025 | -78.17% |
| Dec 31, 2024 | -28.45% |
| Sep 30, 2024 | -53.12% |
| Jun 30, 2024 | 238.47% |
| Mar 31, 2024 | 316.79% |
| Dec 31, 2023 | -93.62% |
| Sep 30, 2023 | -106.42% |